Von Willebrand Disease clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Minimize Menorrhagia in Women With Von Willebrand Disease
Sorry, in progress, not accepting new patients
This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.
San Francisco, California and other locations
Last updated: